Sven Dethlefs, PhD
Sven Dethlefs, PhD
Chief Executive Officer
Sven Dethlefs, PhD, is a global pharmaceutical executive with more than 25 years of experience spanning P&L leadership, R&D and portfolio strategy, operations and manufacturing, and business development and M&A. Prior to joining PureTech Health (LSE: PRTC) to lead PureTech-founded Celea Therapeutics, Sven served as Executive Vice President and CEO of Teva North America, where he oversaw the company’s U.S. and Canadian businesses across specialty, biosimilars, and generics, with full P&L responsibility for approximately $8 billion in annual revenue. Sven holds a PhD in biochemistry and was previously a partner at McKinsey & Company.
“We are excited to launch Celea Therapeutics and advance the first head-to-head Phase 3 trial in idiopathic pulmonary fibrosis with our lead candidate, deupirfenidone. We believe this program has the potential to set a new standard of care in a disease with significant unmet need. With a uniquely experienced team and a committed investor syndicate, we believe Celea is well positioned to become a leading company in the field of severe respiratory diseases.”